Long-Term Effectiveness and Safety of Sirolimus Stent Implantation for Coronary In-Stent RestenosisResults of the TRUE (Tuscany Registry of Sirolimus for Unselected In-Stent Restenosis) Registry at 4 Years
Francesco Liistro, MD*,*,
Massimo Fineschi, MD ,
Simone Grotti, MD*,
Paolo Angioli, MD*,
Arcangelo Carrera, MD,
Kenneth Ducci, MD*,
Tommaso Gori, MD,
Giovanni Falsini, MD*,
Carlo Pierli, MD and
Leonardo Bolognese, MD*
* Cardiovascular Department, San Donato Hospital, Arezzo, Italy
Cardiovascular Department, Le Scotte Hospital, Siena, Italy
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Kaplan-Meier Survival Curves in the Whole Study Group
Survival free from major adverse cardiac events (MACE) and ischemia-driven target lesion revascularization (IDTLR) at 4-year follow-up.
|
|
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Kaplan-Meier Event-Free Survival Curves in Diabetic Population
Survival free from the combined end point of cardiac death, myocardial infarction, and IDTLR at 4-year follow-up in patients with and without diabetes. Abbreviations as in Figure 1.
|
|
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Kaplan-Meier Survival Curves for IDTLR in Diabetic Population
Survival free from IDTLR at 4-year follow-up in patients with and without diabetes. Abbreviation as in Figure 1.
|
|
|
